AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright

Key Points

• HC Wainwright reiterated its “Buy” rating on AnaptysBio and set a $95 price target, implying approximately 66.7% upside from the stock’s reported $56.98 price.
• Analyst sentiment remains broadly positive: nine analysts rate the stock a Buy, while the consensus rating is “Moderate Buy” with an average price target of $82.
• AnaptysBio shares fell 1.3% in mid-day trading, while several institutional investors—including JPMorgan Chase and Arrowstreet Capital—recently increased or initiated positions.

AnaptysBio (NASDAQ:ANAB - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $95.00 price target on the biotechnology company's stock. HC Wainwright's price objective points to a potential upside of 66.73% from the stock's current price.

Other equities research analysts have also issued research reports about the company. UBS Group upped their target price on AnaptysBio from $60.00 to $76.00 and gave the company a "buy" rating in a research report on Wednesday, May 13th. Barclays boosted their price target on AnaptysBio from $63.00 to $75.00 and gave the company an "overweight" rating in a research note on Wednesday, May 13th. Wall Street Zen cut AnaptysBio from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 16th. Zacks Research downgraded shares of AnaptysBio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, June 2nd. Finally, Piper Sandler lowered their price objective on shares of AnaptysBio from $95.00 to $93.00 and set an "overweight" rating for the company in a research note on Monday, May 4th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, AnaptysBio has a consensus rating of "Moderate Buy" and a consensus price target of $82.00.

AnaptysBio Stock Down 1.3%

AnaptysBio stock traded down $0.76 during mid-day trading on Monday, hitting $56.98. 29,706 shares of the stock were exchanged, compared to its average volume of 716,005. AnaptysBio has a 12 month low of $11.40 and a 12 month high of $72.36. The firm's fifty day simple moving average is $58.56 and its two-hundred day simple moving average is $58.83. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -52.76 and a beta of 0.72.

Institutional Trading of AnaptysBio

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC grew its stake in shares of AnaptysBio by 153.3% during the 1st quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company's stock worth $558,000 after acquiring an additional 18,165 shares during the period. Creative Planning raised its stake in AnaptysBio by 26.9% in the 2nd quarter. Creative Planning now owns 16,854 shares of the biotechnology company's stock valued at $374,000 after acquiring an additional 3,571 shares during the period. JPMorgan Chase & Co. lifted its holdings in AnaptysBio by 1,631.6% during the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company's stock valued at $5,497,000 after purchasing an additional 233,325 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in AnaptysBio during the second quarter valued at about $528,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in AnaptysBio during the second quarter valued at about $3,348,000.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source